A well-established approach to stimulating CD4+ T helper responses in cancer vaccines involves using xenogeneic or non-tumor-specific peptides, such as the synthetic helper peptide PADRE (derived from keyhole limpet hemocyanin [KLH]) and tetanus toxoid-derived helper peptides.29 The gene discussed is CD4; the disease is neoplasm.